Friday, August 19, 2022 11:52:33 AM
I 100% agree "The fact that the company feels confident enough to approach the fda with the 210 data leads me to believe it was sufficient to achieve an endpoint change. "
I also think this may be a blessing in disguise as Bucci is a perfect product for Long Haul Covid19 IMO, and that is based on what is already known.... What if long haulers need a life time drug, like Lupus, MS, RA patients like me do? We know Bucci has been used for RA for 30 years, safely, as a daily pill.
And what if Bucci works as a daily pill for long haul covid19. In other words, Long Haul Covid19 may need a life time time drug, and $RVVTF
So moving the end points is perfect for that. Some data is claiming that a huge % of Covid19 survivors have long Covid. What if the $RVVTF data shows that no one that got the real Bucci has long haul covid19? That may be a stretch actually, but we know enough to connect the dots and predict that Bucci should also be a gang buster daily use drug for long Haul covid19.
I also think this may be a blessing in disguise as Bucci is a perfect product for Long Haul Covid19 IMO, and that is based on what is already known.... What if long haulers need a life time drug, like Lupus, MS, RA patients like me do? We know Bucci has been used for RA for 30 years, safely, as a daily pill.
And what if Bucci works as a daily pill for long haul covid19. In other words, Long Haul Covid19 may need a life time time drug, and $RVVTF
So moving the end points is perfect for that. Some data is claiming that a huge % of Covid19 survivors have long Covid. What if the $RVVTF data shows that no one that got the real Bucci has long haul covid19? That may be a stretch actually, but we know enough to connect the dots and predict that Bucci should also be a gang buster daily use drug for long Haul covid19.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
